Compare BLCO & WH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLCO | WH |
|---|---|---|
| Founded | 1853 | 2017 |
| Country | Canada | United States |
| Employees | N/A | 2000 |
| Industry | Ophthalmic Goods | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.5B |
| IPO Year | 2022 | 2017 |
| Metric | BLCO | WH |
|---|---|---|
| Price | $16.46 | $85.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | $18.45 | ★ $90.73 |
| AVG Volume (30 Days) | 417.4K | ★ 1.1M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.00% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.50 |
| Revenue | ★ $5,101,000,000.00 | $1,429,000,000.00 |
| Revenue This Year | $8.63 | $6.72 |
| Revenue Next Year | $5.58 | $5.84 |
| P/E Ratio | ★ N/A | $34.54 |
| Revenue Growth | ★ 6.47 | 1.49 |
| 52 Week Low | $10.45 | $69.21 |
| 52 Week High | $18.92 | $92.69 |
| Indicator | BLCO | WH |
|---|---|---|
| Relative Strength Index (RSI) | 49.85 | 65.07 |
| Support Level | $16.35 | $85.39 |
| Resistance Level | $16.81 | $88.34 |
| Average True Range (ATR) | 0.47 | 2.43 |
| MACD | 0.11 | 0.71 |
| Stochastic Oscillator | 72.63 | 87.27 |
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
As of Dec. 31, 2025, Wyndham Hotels & Resorts operates 869,000 rooms across more than 20 brands predominantly in the economy and midscale segments. Ramada is the largest brand, representing around 14% of all rooms, with Days Inn (13%) and Super 8 (10%) the next two largest brands, as of the end of 2025. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represented 58% of total rooms in 2025.